ImmuCell Corporation (FRA:IUL)

Market Cap	45.84M +0.0%
Revenue (ttm)	23.67M +16.5%
Net Income	1.98M
EPS	0.22
Shares Out	n/a
PE Ratio	23.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	95
Open	5.35
Previous Close	5.50
Day's Range	5.35 - 5.35
52-Week Range	3.88 - 6.25
Beta	n/a
RSI	41.35
Earnings Date	Feb 25, 2026

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Masti...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1982
• Employees: 84
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IUL

Financial Performance

In 2024, ImmuCell's revenue was $26.49 million, an increase of 51.64% compared to the previous year's $17.47 million. Losses were -$2.16 million, -62.65% less than in 2023.

Financial numbers in USD